That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But the company ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...

Gold edged higher in Asia amid losses in U.S. stock-index futures. The precious metal's direction is likely to be determined by equities' direction and risk appetite, said Fawad Razaqzada, a market ...

This report covers recent developments in the health sector, including proposed US federal budget cuts affecting scientific ...

Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...

Novo Nordisk shares rose by more than 5% after the Danish weight-loss drug maker said the Food and Drug Administration accepted a new drug application for a pill form of its popular Wegovy injection.

Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on the ...

A decision is expected in the fourth quarter of 2025.